Biogen (($CC:HTER)) announced an update on their ongoing clinical study. Biogen Inc. (BIIB) has announced an update on its ...

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024 Published. Oct 26, 2024 8:15pm EDT.

Biogen has announced that it has initiated a phase 3 study of investigational felzartamab in adults with primary membranous ...

(RTTNews) - Biogen Inc. (BIIB) announced that results from the Phase 2 IGNAZ study evaluating felzartamab, an investigational anti-CD38 monoclonal antibody, in individuals with IgA nephropathy or ...

Global Phase 3 PROMINENT study will evaluate the efficacy and safety of felzartamab, as compared to tacrolimus, in adults with primary membranous nephropathy (PMN)There are currently no therapies ...

Biogen acquired the rights to felzartamab, which is already in Phase 3 studies in late antibody-mediated rejection in adult kidney transplant recipients and in IgA nephropathy, as part of last ...

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy GlobeNewswire 5d Nasdaq Composite hits record high; See Nasdaq-100's 10 best and worst YTD performers ...

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an ...